Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $105 from $92 and keeps a Buy rating on the shares. The firm attended the Endocrine Society’s Annual Meeting where obesity remained the hottest topic and what’s coming up next in the pipeline and how to preserve (healthy/functional) lean muscle mass. Dr. Ashley Shoemaker stressed the importance of genetic testing for pediatric patients to a packed room and shared a link to Rhythm’s testing program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Promising Potential of Rhythm Pharmaceuticals’ Treatments for Hypothalamic Obesity Drives Buy Rating
- Buy Rating Affirmed for Rhythm Pharmaceuticals on Promising Data and Market Expansion Potential
- Rhythm Pharmaceuticals’ Promising MC4R Agonist Portfolio: Strong Phase 3 Results and Strategic Market Expansion
- Top 3 Trending Stocks, According to Analysts – 7/11/2025
- Rhythm Pharmaceuticals Announces Stock Offering Agreement